Article in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Yanyan CaiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-2779-6163
Peihua ZhaoVIB-KU Leuven Center for Cancer Biology, VIB, Leuven 3000, Belgium.
Fan WuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Huiyong ZhaoAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-2327-7833
Hong ShaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Antonio MarraDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-7310-7824
Payal PatelHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Elizabeth O'ConnellHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0009-0004-0730-4901
Emma FinkDepartment of Cancer Biology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL 60153, USA.ORCID 0009-0002-8506-0995
Matthew M MieleProteomics Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7495-2133
Zhuoning LiProteomics Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Elisa De StanchinaAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-3873-315X
Emiliano CoccoDepartment of Biochemistry and Molecular Biology/Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.ORCID 0000-0002-1397-2656
Pedram RazaviHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-4236-0576
Eneda ToskaSidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.ORCID 0000-0002-8974-9792
Sean W FanningDepartment of Cancer Biology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL 60153, USA.ORCID 0000-0002-9428-0060
Guotai XuNational Institute of Biological Sciences (NIBS), Beijing 102206, China.ORCID 0000-0001-5265-3407
Anna A SablinaVIB-KU Leuven Center for Cancer Biology, VIB, Leuven 3000, Belgium.ORCID 0000-0001-9526-4014
Maurizio ScaltritiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-5522-1447
Sarat ChandarlapatyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-4532-8053
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Overcoming Resistance to Targeted Therapy in Breast CancerR35CA305347 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty · 2025 to 2026
$2.1M
Defining mechanisms of resistance to hormonal therapy in breast cancerR01CA234361 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, SOLIT, DAVID B. · 2019 to 2023
$2.0M
Defining the impact of mutant oncogene zygosityR01CA245069 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT · 2020 to 2024
$2.0M
Mechanisms by which histone methyltransferases regulate nuclear receptor activity and response to therapy in hormone-driven tumors.R01CA276187 · NCI · JOHNS HOPKINS UNIVERSITY · PI Eneda Toska · 2023 to 2026
$1.5M
Structural-Transcriptional Relationships that Improve Y537S Estrogen Receptor AntagonismR37CA279341 · NCI · LOYOLA UNIVERSITY CHICAGO · PI Sean William Fanning · 2023 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers. · full record | OpenQuestion